Status:
COMPLETED
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Pfizer
Conditions:
N/A - Healthy Subjects
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
Eligibility Criteria
Inclusion
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECGs), and clinical laboratory determinations
Exclusion
- Any significant acute or chronic medical illness, history of hypotension, history or evidence of abnormal bleeding or coagulation disorders, significant head injury within the last 2 years
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT02262533
Start Date
June 1 2007
End Date
June 1 2007
Last Update
August 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bms Clinical Research Center
Hamilton, New Jersey, United States, 08690